keyword
MENU ▼
Read by QxMD icon Read
search

alcoholic hepatitis guidelines

keyword
https://www.readbyqxmd.com/read/29607054/non-alcoholic-steatofibrosis-nasf-can-independently-predict-mortality-in-patients-with-non-alcoholic-fatty-liver-disease-nafld
#1
Pegah Golabi, Maria Stepanova, Huong T Pham, Rebecca Cable, Nila Rafiq, Haley Bush, Trevor Gogoll, Zobair M Younossi
Background: Hepatic fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) independently predicts mortality. Given liver biopsy's invasive nature, non-invasive method to assess hepatic steatosis and fibrosis provides NAFLD risk stratification algorithm in clinical practice. NAFLD fibrosis score (NFS) is simple and non-invasive predictive model recommended by American Association for the Study of Liver Disease (AASLD) Guideline to identify patients with NAFLD with fibrosis risk...
2018: BMJ Open Gastroenterology
https://www.readbyqxmd.com/read/29601997/effectiveness-of-a-carbohydrate-restricted-diet-to-treat-non-alcoholic-fatty-liver-disease-in-adolescents-with-obesity-trial-design-and-methodology
#2
Shima Dowla, May Pendergrass, Mark Bolding, Barbara Gower, Kevin Fontaine, Ambika Ashraf, Taraneh Soleymani, Shannon Morrison, Amy Goss
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder among children in the developed world and can progress to cirrhosis, hepatocellular carcinoma, and liver failure. No evidence-based dietary guidelines exist on the most effective diet prescription to treat NAFLD. OBJECTIVE: To compare the effect of a carbohydrate (CHO)-restricted diet vs fat-restricted diet, the current standard of care, on changes in hepatic fat infiltration, body composition, and metabolic health over an 8-week period among overweight and obese children diagnosed with NAFLD...
March 27, 2018: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/29568202/differing-profiles-of-people-diagnosed-with-acute-and-chronic-hepatitis-b-virus-infection-in-british-columbia-canada
#3
Mawuena Binka, Zahid A Butt, Stanley Wong, Mei Chong, Jane A Buxton, Nuria Chapinal, Amanda Yu, Maria Alvarez, Maryam Darvishian, Jason Wong, Gina McGowan, Mikhail Torban, Mark Gilbert, Mark Tyndall, Mel Krajden, Naveed Z Janjua
AIM: To describe the characteristics of people diagnosed with acute and chronic hepatitis B virus (HBV) infection in British Columbia (BC). METHODS: We used data from the BC Hepatitis Testers Cohort (BC-HTC), which includes all individuals tested for hepatitis C virus (HCV) or human immunodeficiency virus (HIV) or those diagnosed with HBV or active tuberculosis in BC since 1990. These data were integrated with prescription drug, medical visit, hospitalization and mortality data...
March 21, 2018: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29535057/no-difference-in-effectiveness-of-8-vs-12-weeks-of-ledipasvir-and-sofosbuvir-for-treatment-of-hepatitis-c-in-black-patients
#4
Julia L Marcus, Leo B Hurley, Scott Chamberland, Jamila H Champsi, Laura C Gittleman, Daniel G Korn, Jennifer B Lai, Jennifer O Lam, Mary Patricia Pauly, Charles P Quesenberry, Joanna Ready, Varun Saxena, Suk Seo, David J Witt, Michael J Silverberg
BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-week course. Guidelines recommend a 12-week treatment course for black patients, but studies have not compared the effectiveness of 8 vs 12 weeks in black patients who are otherwise eligible for an 8-week treatment regimen. METHODS: We conducted an observational study of Kaiser Permanente Northern California members with HCV genotype 1 infection who were eligible for 8 weeks of treatment with ledipasvir and sofosbuvir (treatment-naïve, no cirrhosis, no HIV infection, level of HCV RNA <6 million IU/mL) and were treated for 8 or 12 weeks from October 2014 through December 2016...
March 10, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29493093/highlights-of-the-2017-european-aids-clinical-society-eacs-guidelines-for-the-treatment-of-adult-hiv-positive-persons-version-9-0
#5
L Ryom, C Boesecke, M Bracchi, J Ambrosioni, A Pozniak, J Arribas, G Behrens, Pgm Mallon, M Puoti, A Rauch, J M Miro, O Kirk, C Marzolini, J D Lundgren, M Battegay
BACKGROUND: The European AIDS Clinical Society (EACS) Guidelines have since 2005 provided multidisciplinary recommendations for the care of HIV-positive persons in geographically diverse areas. GUIDELINE HIGHLIGHTS: Major revisions have been made in all sections of the 2017 Guidelines: antiretroviral treatment (ART), comorbidities, coinfections and opportunistic diseases. Newly added are also a summary of the main changes made, and direct video links to the EACS online course on HIV Management...
March 1, 2018: HIV Medicine
https://www.readbyqxmd.com/read/29489473/worldwide-incidence-of-hepatocellular-carcinoma-cases-attributable-to-major-risk-factors
#6
Aileen Baecker, Xing Liu, Carlo La Vecchia, Zuo-Feng Zhang
To facilitate regionally specific liver cancer prevention and control, this study estimates the fraction of hepatocellular carcinoma (HCC) cases attributable to five major liver cancer risk factors by geographic region. Prevalence estimates of major HCC risk factors, including chronic infection with hepatitis B and hepatitis C, alcohol drinking, tobacco smoking, obesity, and diabetes, were extracted for each country from the literature, along with recent incidence and risk estimate data, to calculate regionally specific population attributable fractions...
February 27, 2018: European Journal of Cancer Prevention
https://www.readbyqxmd.com/read/29476581/persistently-altered-liver-test-results-in-hepatitis-c-patients-after-sustained-virological-response-with-direct-acting-antivirals
#7
Antonio Olveira, Lourdes Domínguez, Jesús Troya, Ana Arias, Federico Pulido, Pablo Ryan, Laura María Benítez, Juan González-García, María Luisa Montes
Guidelines recommend evaluating persistent alteration of liver tests in HCV-infected patients after sustained virological response (SVR) and its influence on liver disease progression. We studied the prevalence, aetiology, associated factors, and evolutionary implications of persistent alteration of liver tests in HCV patients after direct-acting antivirals (DAA) -induced SVR. This was a prospective study of HCV-infected patients and SVR after DAA. Those with another previously diagnosed liver disease were excluded...
February 24, 2018: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29431526/the-potential-role-of-statins-in-treating-liver-disease
#8
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Anastasia Skalkou, Ioanna Zografou, Vasilios G Athyros
Statins are commonly use for the management of dyslipidemia, worldwide. Various studies have demonstrated that statins offer significant reduction in the risk of cardiovascular morbidity and mortality. However, this class of drugs has been implicated in potential liver toxicity, thus has been considered as a 'forbidden-drug' in patients with increased liver enzymes. Areas covered: Studies have shown that statins might offer clinical benefits in the setting of viral hepatitis, progression of cirrhosis, and hepatocellular carcinoma...
April 2018: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29336434/acg-clinical-guideline-alcoholic-liver-disease
#9
Ashwani K Singal, Ramon Bataller, Joseph Ahn, Patrick S Kamath, Vijay H Shah
Alcoholic liver disease (ALD) comprises a clinical-histologic spectrum including fatty liver, alcoholic hepatitis (AH), and cirrhosis with its complications. Most patients are diagnosed at advanced stages and data on the prevalence and profile of patients with early disease are limited. Diagnosis of ALD requires documentation of chronic heavy alcohol use and exclusion of other causes of liver disease. Prolonged abstinence is the most effective strategy to prevent disease progression. AH presents with rapid onset or worsening of jaundice, and in severe cases may transition to acute on chronic liver failure when the risk for mortality, depending on the number of extra-hepatic organ failures, may be as high as 20-50% at 1 month...
February 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29185250/management-of-hepatitis-c-in-decentralised-versus-centralised-drug-substitution-programmes-and-minimally-invasive-point-of-care-tests-to-close-gaps-in-the-hcv-cascade
#10
Andrea Bregenzer, Anna Conen, Jürg Knuchel, Andrée Friedl, Franz Eigenmann, Martin Näf, Peter Ackle, Martin Roth, Christoph Andreas Fux
BACKGROUND: In Switzerland, intravenous drug use accounts for the majority of hepatitis C virus (HCV) infections. Early HCV treatment prevents further transmissions and reduces morbidity and mortality due to decompensated liver cirrhosis and hepatocellular carcinoma. Nevertheless, patients in drug substitution programmes are often insufficiently screened and treated. AIM: The aim was to compare the current state of HCV management in centralised and decentralised drug substitution programmes of the canton Aargau...
November 29, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/29096421/glucocorticosteroids-for-people-with-alcoholic-hepatitis
#11
REVIEW
Chavdar S Pavlov, Daria L Varganova, Giovanni Casazza, Emmanuel Tsochatzis, Dimitrinka Nikolova, Christian Gluud
BACKGROUND: Alcoholic hepatitis is a form of alcoholic liver disease, characterised by steatosis, necroinflammation, fibrosis, and potential complications to the liver disease. Typically, alcoholic hepatitis presents in people between 40 and 50 years of age. Alcoholic hepatitis can be resolved if people abstain from drinking, but the risk of death will depend on the severity of the liver damage and abstinence from alcohol. Glucocorticosteroids are used as anti-inflammatory drugs for people with alcoholic hepatitis...
November 2, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29075369/acute-on-chronic-liver-failure-in-a-multi-ethnic-asian-city-a-comparison-of-patients-identified-by-asia-pacific-association-for-the-study-of-the-liver-and-european-association-for-the-study-of-the-liver-definitions
#12
Anandraj Selva Rajoo, Seng-Gee Lim, Wah Wah Phyo, Thandar Tun, Yock-Young Dan, Yin-Mei Lee, How-Cheng Low, Kieron Lim, Poh-Seng Tan, Guan-Huei Lee
AIM: To explore the applicability of the Asia-Pacific Association for the Study of the Liver (APASL) and European Association for the Study of the Liver (EASL) guidelines for acute-on-chronic liver failure (ACLF) in profiling patients and determining the outcome. METHODS: Patients admitted to a tertiary hospital in Singapore with acute decompensation of liver disease from January 2004 to July 2014 are screened for ACLF according to the APASL and EASL criteria. The patients' data (including basic demographics, information about existing chronic liver disease, information about the acute decompensation, relevant laboratory values during admission, treatment, and outcome) are retrospectively analyzed to determine the background, precipitating factors and outcome...
October 8, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/29074409/global-prevalence-of-injecting-drug-use-and-sociodemographic-characteristics-and-prevalence-of-hiv-hbv-and-hcv-in-people-who-inject-drugs-a-multistage-systematic-review
#13
Louisa Degenhardt, Amy Peacock, Samantha Colledge, Janni Leung, Jason Grebely, Peter Vickerman, Jack Stone, Evan B Cunningham, Adam Trickey, Kostyantyn Dumchev, Michael Lynskey, Paul Griffiths, Richard P Mattick, Matthew Hickman, Sarah Larney
BACKGROUND: Sharing of equipment used for injecting drug use (IDU) is a substantial cause of disease burden and a contributor to blood-borne virus transmission. We did a global multistage systematic review to identify the prevalence of IDU among people aged 15-64 years; sociodemographic characteristics of and risk factors for people who inject drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) among PWID. METHODS: Consistent with the GATHER and PRISMA guidelines and without language restrictions, we systematically searched peer-reviewed databases (MEDLINE, Embase, and PsycINFO; articles published since 2008, latest searches in June, 2017), searched the grey literature (websites and databases, searches between April and August, 2016), and disseminated data requests to international experts and agencies (requests sent in October, 2016)...
December 2017: Lancet Global Health
https://www.readbyqxmd.com/read/28989095/risk-factors-and-prevention-of-hepatocellular-carcinoma-in-the-era-of-precision-medicine
#14
REVIEW
Naoto Fujiwara, Scott L Friedman, Nicolas Goossens, Yujin Hoshida
Patients who develop chronic fibrotic liver disease, caused by viral or metabolic aetiologies, are at a high risk of developing hepatocellular carcinoma (HCC). Even after complete HCC tumour resection or ablation, the carcinogenic tissue microenvironment in the remnant liver can give rise to recurrent de novo HCC tumours, which progress into incurable, advanced-stage disease in most patients. Thus, early detection and prevention of HCC development is, in principle, the most impactful strategy to improve patient prognosis...
March 2018: Journal of Hepatology
https://www.readbyqxmd.com/read/28986139/restrictions-for-reimbursement-of-interferon-free-direct-acting-antiviral-drugs-for-hcv-infection-in-europe
#15
Alison D Marshall, Evan B Cunningham, Stine Nielsen, Alessio Aghemo, Hannu Alho, Markus Backmund, Philip Bruggmann, Olav Dalgard, Carole Seguin-Devaux, Robert Flisiak, Graham R Foster, Liana Gheorghe, David Goldberg, Ioannis Goulis, Matthew Hickman, Patrick Hoffmann, Ligita Jancorienė, Peter Jarcuska, Martin Kåberg, Leondios G Kostrikis, Mihály Makara, Matti Maimets, Rui Tato Marinho, Mojca Matičič, Suzanne Norris, Sigurður Ólafsson, Anne Øvrehus, Jean-Michel Pawlotsky, James Pocock, Geert Robaeys, Carlos Roncero, Marieta Simonova, Jan Sperl, Michele Tait, Ieva Tolmane, Stefan Tomaselli, Marc van der Valk, Adriana Vince, Gregory J Dore, Jeffrey V Lazarus, Jason Grebely
All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or more, represent a major clinical advance. However, the high list price of DAAs has led many governments to restrict their reimbursement. We reviewed the availability of, and national criteria for, interferon-free DAA reimbursement among countries in the European Union and European Economic Area, and Switzerland. Reimbursement documentation was reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, drug or alcohol use, prescriber type, and HIV co-infection restrictions...
February 2018: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28970146/association-between-hepatic-steatosis-measured-by-controlled-attenuation-parameter-and-fibrosis-burden-in-chronic-hepatitis-b
#16
Wai-Kay Seto, Rex W H Hui, Lung-Yi Mak, James Fung, Ka-Shing Cheung, Kevin S H Liu, Danny Ka-Ho Wong, Ching-Lung Lai, Man-Fung Yuen
BACKGROUND & AIMS: The interaction between chronic hepatitis B (CHB) and hepatic steatosis is poorly understood. We investigated whether measurement of controlled attenuation parameter (CAP), a non-invasive method to quantify steatosis, can assist in monitoring patients with CHB. METHODS: We performed transient elastography, to measure liver stiffness, and made CAP measurements in 1606 patients with CHB (898 treated with nucleoside analogues, for a median 75...
September 29, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28952271/-dictamni-cortex-powder-induced-liver-injury-based-on-integrated-evidence-chain
#17
Yi-Xue Huang, Yu-Ming Guo, Yong-Feng Zhou, Cong-En Zhang, Jing Jing, Shi-Jing Liu, Na-Na Zhang, Jing-Yuan Song, Xiao-He Xiao, Jia-Bo Wang
A typical clinical case of taking Dictamni Cortex(Baixianpi) powder was analyzed to study liver damage caused by Dictamni Cortex. Liver damage was diagnosed according to the integrated evidence chain method recommended by the Guideline for Diagnosis and Treatment of Herb-Induced Liver Injury. By analyzing clinical history and biochemistry and imaging examinations, underlying diseases, such as viral hepatitis, autoimmune liver disease and alcoholic liver disease, were excluded. Through the investigation of medication history, we made it clear that the patient only took Dictamni Cortex powder during the period, and thus suspected that the liver injury was induced by Dictamni Cortex...
February 2017: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/28933748/dietary-composition-independent-of-weight-loss-in-the-management-of-non-alcoholic-fatty-liver-disease
#18
REVIEW
Tannaz Eslamparast, Puneeta Tandon, Maitreyi Raman
Poor dietary composition is an important factor in the progression of non-alcoholic fatty liver disease (NAFLD). The majority of NAFLD patients follow diets with overconsumption of simple carbohydrates, total and saturated fat, with reduced intake of dietary fiber and omega-3 rich foods. Although lifestyle modifications including weight loss and exercise remain the keystone of NAFLD management, modifying dietary composition with or without a calorie-restricted diet may also be a feasible and sustainable strategy for NAFLD treatment...
July 26, 2017: Nutrients
https://www.readbyqxmd.com/read/28692443/a-single-test-combining-blood-markers-and-elastography-is-more-accurate-than-other-fibrosis-tests-in-the-main-causes-of-chronic-liver-diseases
#19
Alexandra Ducancelle, Vincent Leroy, Julien Vergniol, Nathalie Sturm, Brigitte Le Bail, Jean Pierre Zarski, Eric Nguyen Khac, Dominique Salmon, Victor de Ledinghen, Paul Calès
BACKGROUND AND GOAL: International guidelines suggest combining a blood test and liver stiffness measurement (LSM) to stage liver fibrosis in chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD). Therefore, we compared the accuracies of these tests between the main etiologies of chronic liver diseases. STUDY: Overall, 1968 patients were included in 5 etiologies: CHC: 698, chronic hepatitis B: 152, human immunodeficiency virus/CHC: 628, NAFLD: 225, and alcoholic liver disease (ALD): 265...
August 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28688543/liver-steatosis-the-new-epidemic-of-the-third-millennium-benign-liver-state-or-silent-killer
#20
REVIEW
Claudio Puoti, Maria Giuseppa Elmo, Daniela Ceccarelli, Michela Ditrinco
Until the end of the 90's of the last century, rather little attention was paid to the issue of the non-alcoholic fatty liver disease (NAFLD), perhaps due to the fact that the newly discovered hepatitis C virus did attract a paramount interest of hepatologists and researchers. On the other side, fatty liver was considered a relatively uncommon cause of liver damage, occurring almost exclusively in obese females, often associated with non-insulin dependent diabetes mellitus (NIDDM), and with a relatively benign prognosis...
December 2017: European Journal of Internal Medicine
keyword
keyword
120683
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"